title: Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration.
abstract: The results of a patient with exudative age-related macular degeneration who received an intravitreal injection of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Paris, France) in the right eye are described. A complete ocular examination as well as color fundus photography, optical coherence tomography, fluorescein angiography, microperimetry, full-field electroretinography, and multifocal electroretinography were performed and repeated 1 month later. The patient experienced subjective and objective improvement of visual acuity with a decrease in intraretinal and subretinal fluid. Microperimetric improvement also occurred. Electroretinographic changes were noted from baseline to the 30-day follow-up. No adverse events were observed at any time point. Ziv-aflibercept demonstrated short-term safety and efficacy after intravitreal administration for neovascular macular degeneration.
authors.forename: João Rafael
authors.initials: JR
authors.lastname: de Oliveira Dias
authors.forename: Camilla Oliveira
authors.initials: CO
authors.lastname: Xavier
authors.forename: André
authors.initials: A
authors.lastname: Maia
authors.forename: Nilva Simeren Bueno
authors.initials: NS
authors.lastname: de Moraes
authors.forename: Carsten
authors.initials: C
authors.lastname: Meyer
authors.forename: Michel Eid
authors.initials: ME
authors.lastname: Farah
authors.forename: Eduardo Büchele
authors.initials: EB
authors.lastname: Rodrigues
mesh_terms: D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D004596:Electroretinography; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D010781:Photography; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor